- Home
- IKT vs KRRO Comparison
IKT vs KRRO Comparison
Compare IKT & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- KRRO
- Stock Information
- Founded
- IKT 2008
- KRRO 2014
- Country
- IKT United States
- KRRO United States
- Employees
- IKT N/A
- KRRO N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- IKT Health Care
- KRRO Health Care
- Exchange
- IKT Nasdaq
- KRRO Nasdaq
- Market Cap
- IKT 140.5M
- KRRO 125.4M
- IPO Year
- IKT 2020
- KRRO 2019
- Fundamental
- Price
- IKT $1.85
- KRRO $12.90
- Analyst Decision
- IKT Buy
- KRRO Strong Buy
- Analyst Count
- IKT 2
- KRRO 7
- Target Price
- IKT $8.00
- KRRO $85.67
- AVG Volume (30 Days)
- IKT 526.2K
- KRRO 99.7K
- Earning Date
- IKT 08-13-2025
- KRRO 08-12-2025
- Dividend Yield
- IKT N/A
- KRRO N/A
- EPS Growth
- IKT N/A
- KRRO N/A
- EPS
- IKT N/A
- KRRO N/A
- Revenue
- IKT N/A
- KRRO $4,821,000.00
- Revenue This Year
- IKT N/A
- KRRO $65.08
- Revenue Next Year
- IKT N/A
- KRRO N/A
- P/E Ratio
- IKT N/A
- KRRO N/A
- Revenue Growth
- IKT N/A
- KRRO N/A
- 52 Week Low
- IKT $1.12
- KRRO $10.29
- 52 Week High
- IKT $4.20
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- IKT 47.71
- KRRO 51.40
- Support Level
- IKT $1.80
- KRRO $12.27
- Resistance Level
- IKT $2.09
- KRRO $15.15
- Average True Range (ATR)
- IKT 0.14
- KRRO 1.13
- MACD
- IKT 0.03
- KRRO 0.25
- Stochastic Oscillator
- IKT 54.72
- KRRO 57.01
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.